AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04132804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
Study NCT02571738 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CHAM
Description: The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
Study NCT02571738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of Care
Study NCT03344835 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03991247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized behavioral therapy program delivered by internet for insomnia management
Description: The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm).
Study NCT03991247 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized behavioral therapy program delivered by internet for insomnia management
Description: The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm).
Study NCT03991247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa treatment
Description: Spa treatment is harmonized in the different stations. It consists in:~* a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~* an institutional follow-up: support, help and monitoring of patients during spa treatment~* Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C.
Study NCT02357433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Doses CPFA
Study NCT01579864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine
Description: Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
Study NCT01579864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
Study NCT00848432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
Study NCT01580098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring for patients with Diabetes mellitus type 2
Description: Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
Study NCT03033836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV treatment
Description: Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
Study NCT02933476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Stimulation
Description: The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
Study NCT04529460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 antibody point of care test kit
Description: A disponible point of care test that identifies the presence of antibodies to COVID-19
Study NCT03370302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules.
Study NCT02465970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARSTIM
Description: Multifocal transcranial direct current stimulation.~* CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~* The stimulation is applied during a 60 min session
Study NCT02465970 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham TDCS
Study NCT03959189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERX-963
Description: Active medicine
Study NCT03959189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Comparator
Study NCT00525252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
Study NCT03915899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIN (Welcome Incoming Neighbor)
Description: WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
Study NCT00525252 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be orally administered for 12 consecutive weeks
Study NCT01302275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Study NCT00376506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation device for dysphagia
Description: A neurostimulation device that is surgically implanted in the swallowing muscles.
Study NCT00376506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External vibrotactile device
Description: A vibrotactile device that is placed on the neck during swallowing.
Study NCT01302275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxcarbazepine
Description: Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Study NCT03836144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Potassium citrate
Study NCT02112968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proscan
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
Study NCT02112968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zyoptix
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
Study NCT03053011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrating bracelet
Description: A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
Study NCT03220789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drilling at low speed
Study NCT03220789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drilling at conventional or high speed
Study NCT03791372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group
Study NCT02112968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supracor
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
Study NCT03446924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidic Acid
Description: To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
Study NCT03446924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice flour
Description: Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
Study NCT03791372 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
Study NCT01259466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
Study NCT01259466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
Study NCT04403867 — intervention group
Intervention type: PROCEDURE
Intervention: Sentinel lymph node (SLN) biosy +/- lymphadenectomy
Description: Evaluation of type and volume of lymph nodal disease
Study NCT02363491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-305
Description: For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
Study NCT00766818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra
Description: Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
Study NCT01837342 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical reserction
Study NCT01837342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiological percutaneous drainage and washing drainage
Study NCT02513446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: Single dose of BI 1026706 on Day 1
Study NCT02513446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
Study NCT03815305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centella Asiatica Extract
Description: centlla asiatica oral drug at 1100 mg dose
Study NCT03815305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical CA
Description: 1% centella asiatica ointment
Study NCT03815305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum jelly
Description: vaseline album
Study NCT02612155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of autologous cord blood
Description: Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
Study NCT02394197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine phosphate
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study NCT02612155 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
Study NCT02511353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Study NCT02511353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for ivermectin.
Study NCT02511353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for ivermectin.
Study NCT02511353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Study NCT02394197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study NCT04341571 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
Study NCT02511353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Study NCT04341571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention.
Study NCT04770974 — intervention group
Intervention type: OTHER
Intervention: Biomarkers and proteomics
Description: Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
Study NCT03724344 — intervention group
Intervention type: OTHER
Intervention: Cross section resaerch
Description: Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
Study NCT02448108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-IPSRT
Description: internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT.
Study NCT02394197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: primaquine
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study NCT02394197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study NCT02378805 — intervention group
Intervention type: DRUG
Intervention: ACE-inhibitor
Description: observational study!
Study NCT01580098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-monitoring for patients with Diabetes mellitus type 2
Description: Nurses are submitting the vital parameters of the patient via mobile device.
Study NCT02448108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Written Psychoeducation
Description: Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
Study NCT02378805 — intervention group
Intervention type: DRUG
Intervention: AT1-inhibitor
Description: observational study!
Study NCT02378805 — intervention group
Intervention type: DRUG
Intervention: HMG-Coenzyme inhibitor (statin)
Description: observational study!
Study NCT04385992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Description: Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
Study NCT00866320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
Study NCT03125733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submucosal tunneling endoscopic septum division
Description: STESD includes 4 steps:~1. Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~2. Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~3. Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~4. Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips.
Study NCT02378805 — intervention group
Intervention type: DRUG
Intervention: Spironolactone
Description: observational study!
Study NCT02378805 — intervention group
Intervention type: DRUG
Intervention: Paricalcitol
Description: observational study!
Study NCT02378805 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: observational study!
Study NCT03255954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling for University Counseling Centers
Description: Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
Study NCT02572336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THR-18
Description: THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
Study NCT02069158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: iv administration
Study NCT02069158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: iv administration
Study NCT02373397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cacicol20
Description: Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
Study NCT02373397 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle only in identical packaging, with identical dosage and administration route.
Study NCT03680248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours.
Study NCT03680248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fasting
Description: Subjects will fast throughout the experiment.
Study NCT03680248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat+Glucose
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.
Study NCT03680248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.
Study NCT03680248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat+Fructose
Description: Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.
Study NCT03680248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
Study NCT02572336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a THR-18 lookalike, to be administered with tPA.
Study NCT02572336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA is a thrombolytic agent. tPA is not an investigational drug.
Study NCT04488822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: 400 mg twice daily for a total daily dose of 800 mg (each capsule contains 200 mg of pexidartinib for oral administration)
Study NCT02572336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator (tPA)
Description: tPA is a thrombolytic agent. tPA is not an investigational drug.